BridgeMD
New treatment option for Mycobacterium Abscessus Lung Disease
Official title The Effect of Rifabutin in Mycobacterium Abscessus With Inducible Clarithromycin Resistance
ClinicalTrials.gov ID: NCT07514364
What this study is testing
What is Rifabutin?
Rifabutin is an investigational medicine, being studied as a potential treatment for mycobacterium abscessus lung disease.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Background: Mycobacterium abscessus, one of the most common species of nontuberculous mycobacterium (NTM), poses a significant clinical challenge due to its natural resistance to antibiotics and high treatment failure rates, particularly in lung diseases. Among its subspecies, M.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adults aged ≥ 18 years
- Diagnosis of pulmonary disease caused by Mycobacterium abscessus confirmed by clinical evaluation and laboratory results
- Antimicrobial susceptibility testing indicating inducible resistance to clarithromycin
- Clinically stable and suitable for antibiotic treatment
- Radiographic evidence of active pulmonary infection
You likely can't join if
- Known hypersensitivity to rifabutin or intolerance to other study medications
- Pregnant or breastfeeding women
See the full eligibility criteria
- Adults aged ≥ 18 years
- Diagnosis of pulmonary disease caused by Mycobacterium abscessus confirmed by clinical evaluation and laboratory results
- Antimicrobial susceptibility testing indicating inducible resistance to clarithromycin
- Clinically stable and suitable for antibiotic treatment
- Radiographic evidence of active pulmonary infection
- Willing and able to provide informed consent
- Known hypersensitivity to rifabutin or intolerance to other study medications
- Pregnant or breastfeeding women
The study team makes the final eligibility decision.
Where it's taking place
- Taipei, Taiwan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Taipei, Taiwan. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.